 ABC News | Tamiflu sales boost Roche results despite efficacy concerns PMLiVE ... but there were solid gains for the firm's blockbuster cancer drugs, with Herceptin (trastuzumab) and Avastin (bevacizumab) both rising 11 per cent to 1.57bn Swiss francs and 1.53bn Swiss francs respectively, and MabThera/Rituxan (rituximab) up 6 ... Roche sales rise thanks to oncology drugs and Tamiflu Roche 1st-qtr 2013 sales grow 6%, driven by cancer drugs |
